Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

NCT07487519 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer (Triple Negative Breast Cancer (TNBC))

Interventions

DRUG: HLX43 DOSE 1 IN ≥2L TNBC
DRUG: HLX43 DOSE 2 IN ≥2L TNBC
DRUG: HLX43 DOSE 1 + HLX10
DRUG: HLX43 DOSE1 IN 1L TNBC
DRUG: HLX43 DOSE 2 IN 1L TNBC
DRUG: HLX43 DOSE2 + HLX10

Sponsor

Shanghai Henlius Biotech